The scale and impact of mental illness across society is huge. One in ten children, and one in four adults (approx. 15 million people) experience mental illness each year, affecting their wellbeing, relationships, and potential ability to work. The economic and social cost has been estimated as £105bn a year in England alone.
New treatments are needed urgently. However, the lack of novel drug targets combined with the challenge of validating them pre-clinically, and the high failure rate in clinical trials have led to a reduced investment in drug discovery and development in the last decade and there have been no new effective types of treatment for over 30 years.
However, there is good news too:
- advances in the understanding of disease biology combined with the emerging genetic data can inform new efforts in drug-discovery
- recent renewed interest from Pharma means there are opportunities for re-investment
- world-leading academic centres and initiatives are already generating new targets
The Psychiatry Consortium partners will share the high risks inherent in drug discovery and, as a collective, will aim to:
- engage the psychiatry academic community globally by providing opportunities for funding, collaboration & access to industry and commercialisation know-how
- work collaboratively with academia to identify and validate novel therapeutic targets and strategies to treat psychiatric diseases
- increase the number of new targets and screening assays, validated to industry standards, to support the discovery and development of new drugs
We take your data protection seriously, for more information read the Psychiatry Consortium Privacy Notice.